EUVIMED · CrossrefJournal
Cardio-Oncology
ISSN 2057-3804 · Springer Science and Business Media LLC
Latest articles
Utilization, safety, and outcome of statin therapy in patients receiving immune checkpoint inhibitors
Incidence and predictors of heart failure among anthracycline-treated older adults with lymphoma
Cardiovascular toxicity of neuro-oncologic therapies: toward a cardio-neuro-oncology framework for risk stratification, surveillance, and management
Dual-axis cardiotoxicity associated with the first-in-class anti-PD-1/VEGF-A bispecific antibody ivonescimab: a narrative review
Cardiotoxicity in oncology: a cancer-centred perspective on current evidence and future directions
Association of endocrine therapy and cardiovascular disease outcomes in patients with estrogen receptor positive breast cancer
Cardiovascular risk factors, NT-proBNP levels and echocardiographic findings in long-term survivors of childhood cancer exposed to anthracyclines
Prevalence of atrial fibrillation in cancer patients treated with radiation therapy: a systematic review and meta-analysis
Celebrating the 30th anniversary of the introduction of cardio-oncology: commentary and the first english translation of the report
Complex cardiac overlap: immune checkpoint inhibitor myocarditis in hypertrophic obstructive cardiomyopathy with subsequent NSTEMI
VEGF-A signalling at the vascular-immune interface: impact of anti-angiogenic agents on cardiovascular homeostasis and anthracycline-induced injury
Cardiovascular effects of chemoradiotherapy in patients with lung cancer: an [18F]FDG PET-CT imaging study
Cardiac calcification and radiation dose to cardiac substructures as predictors of survival in breast cancer patients undergoing thoracic radiotherapy
Integrating coronary artery calcium scoring into radiotherapy planning CT scans to guide cardio-oncology referral in cancer patients: a multicentre prospective feasibility study
EXERT-BCHC: a prospective study of exercise regimens after breast cancer to improve skeletal muscle hypertrophy and conditioning
Cardiotoxicity and safety of zanubrutinib versus chemoimmunotherapy in chronic lymphocytic leukemia: a real-world retrospective cohort study using the TriNetX registry
Pharmacologic prevention of cardiotoxicity in breast cancer: a Bayesian network meta-analysis and meta-regression
Cancer treatment-related cardiovascular toxicity according to the ESC definition in patients receiving CAR T-cell therapy
Psychosocial stress exacerbates doxorubicin-induced cardiotoxicity in adult C57BL/6N mice
Serum hemoglobin-to-creatinine ratio is associated with early surrogate markers of anthracycline-related cardiotoxicity: a retrospective analysis
No detectable early subclinical cardiotoxicity within 12 weeks of thoracic radiotherapy under predominantly low cardiac dose exposure: a prospective cohort study
Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement
Temporal dynamics of cardiac biomarkers in therapy‑related cardiotoxicity: a prospective cardio‑oncology cohort study
Machine learning and plasma growth differentiation factor-15 (GDF15) for early risk stratification of heart failure progression in a long-latency doxorubicin cardiomyopathy model
Environmental endocrine disruptors in cardio-oncology: emerging modifiers of cardiovascular vulnerability in patients with cancer
Effective management of 5-fluorouracil-induced coronary vasospasm allowing chemotherapy continuation: a single-center observational study
Cardiac dysfunction during immune checkpoint inhibitor therapy: association with extracardiac immune-related adverse events
Trends and disparities for co-existent pancreatic cancer and cardiovascular-related deaths: a retrospective 1999–2020 analysis of CDC WONDER data
A smartphone application for cardiovascular rehabilitation in cancer survivors
Addition of malignancy into the CHADS2/CHA2DS2VASc score: better prediction of stroke risk in individuals with cancer and atrial fibrillation
EUVIMED